FDA Reprimands Gilead Over Letairis Statements
The U.S. Food and Drug Administration has chastised Gilead Sciences Inc. for a sales representative's "false and misleading" statements that misbranded the hypertension drug Letairis and minimized "serious risks" associated with...To view the full article, register now.
Already a subscriber? Click here to view full article